The report titled “Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-2019)” . For more mail me: info@daedal-research.com

1. Global Anti-Migraine Drugs Market – Trends and
Opportunities (2014-2019)

2. Scope of the Report
The report titled “Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-2019)”
provides an insight into migraine drugs with a special focus on Triptans. The report also
includes the market value, segmentation, types of diagnosis and treatment for migraine. It
also discusses key growth drivers and upcoming trends of the market. Further, key
manufacturers of anti-migraine drugs like Endo International Inc, Impax Laboratories,
GlaxoSmithKline and Pfizer Inc. are profiled in the report.
Segments Coverage
 Triptans
 Ergot Alkaloids
Company Coverage
 Endo International Inc.
 IMPAX Laboratories Inc.
 GlaxoSmith Kline (GSK)
 Pfizer Inc.
View Report Details

3. Executive Summary
Migraine, a condition of recurring headaches and is accompanied by symptoms like nausea,
vomiting, dizziness and sensitivity to light and noise ranks among the World’s Top 20 disabling
medical illnesses. It is anticipated that launches of many generic migraine drugs over the next
several years will steadily increase diagnosis and drug-treatment rates, leading to sustained
annual global growth of anti-migraine drugs market. Other factors contributing to the growth of
these drugs include awareness among the people about proper diagnosis and treatment of
migraine, rise in medical expenditures and new drugs launches.
Acute migraine treatment market is dominant by Triptans and most of them are available as
pills. Triptans like Sumatriptan and Zolmitriptan are also available as nasal sprays whereas
rizatriptan and zolmitriptan are available as tablets that dissolve in mouth. In next 5-10 years,
cost of migraine drugs is anticipated to decline due to many generic entrants as most of them
are losing their patents. Growing awareness of migraine in the emerging countries and fall in
prices will facilitate the growth of anti-migraine drugs market. In addition, with the
development of new treatment therapies like calcitonin gene-related peptides (CGRP) receptor
antagonist and BOTOX the demand for anti-migraine drugs is anticipated to grow further.
The US is the largest market for anti-migraine drugs and there are number of companies that
manufacture these drugs. Major companies include Impax, Endo Pharmaceuticals, Pfizer,
GlaxoSmith Kline, Nautilus and Allergan.

4. Global Anti Migraine Drugs Market
Nearly ….% people worldwide are affected by migraine, translating into a market size of US$....
billion in 2013. Drivers contributing to the growth of migraine drugs market include awareness
among the people about proper diagnosis and treatment of migraine, rise in medical
expenditures and new drugs launches.
Global Migraine Drugs Market Size (US$ Billion),
2009-2013
• Acute migraine treatment market is dominant by Triptans that accounted for ….% of total
drugs revenue in 2013. Isometheptene are the second highest, accounting for …% of
prescriptions followed by Ergots having a share of …%.
Segmentation of Migraine Drugs by Types, 2013
2008 2009 2010 2011 2012 2013
Triptans
Isometheptene
Ergots

5. The US Anti-Migraine Drugs Market
The US is the largest market globally and accounted for approximately …% of total anti-migraine
drugs revenue in 2013. It is estimated that total number of acute migraine sufferers will increase
from …million in 2012 to … million by 2017 and that of chronic migraine sufferers from … million in
2012 to …… million by 2017.
Total Number of Migraine Sufferers in the US in
Million, 2012E-2017E
• Triptans account for the largest portion of overall anti-migraine drugs consumed in the US. As
more triptan brands become generic in the coming years, it is expected that the demand will
subsequently increase. Relpax brand manufactured by Pfizer has the highest market share.
Figure 9: Market Shares of Triptan by Brands in
the US, 2013
2012E 2013E 2014E 2015E 2016E 2017E
Acute Migraine Sufferers Chronic Migraine Sufferers
Relpax
Imitrex
Maxalt
Zomig
Frova
Treximet
Amerge
Axert
Zegenix

6. Table of Contents
1. Executive Summary
2. Migraine
2.1 An Overview
2.2 Different Types of Migraines
2.2.1 Migraine without Aura
2.2.2 Migraine with Aura
2.2.3 Other Types of Migraine
2.3 Diagnosis and Treatment
3. Anti-Migraine Drugs Market
3.1 Global Anti-Migraine Drugs Market Size (2009-
2013)
3.2 Forecast- Global Anti-Migraine Drugs Market Size
(2014-2019)
3.3 Segmentation by Type of Drugs Used
3.4 Migraine Specific Drug
3.4.1 Triptan
Types of Triptans
Effectiveness of Triptans
Triptan Costs
3.4.2 Tezampanel
3.4.3 Ergots Alkaloids
3.5 Prevalence of Migraine
4. The US Migraine Market
4.1 Migraine Sufferers
4.2 Market Size
4.3 Triptans Sales
5. Market Drivers & Challenges
5.1 Rising Healthcare Expenditures
5.2 Growth of Middle-Aged Population
5.3 Patent Expires of Migraine Drugs
6. Challenges
6.1 Strict Regulations
6.2 Expensive Drugs

7. Table of Contents
7. Upcoming Trends
7.1 Calcitonin Gene-Related Peptides (CGRP)
Antibodies
7.2 BOTOX for Migraine
7.3 Anti-Migraine Headbands & Devices
7.4 New Products Development
8. Competitive Landscape
9. Company Profiles
9.1 Endo International Plc.
9.1.1 Business Description
9.1.2 Financial Overview
9.1.3 Business Strategies
9.2 IMPAX Laboratories Inc.
9.2.1 Business Description
9.2.2 Financial Overview
9.2.3 Business Strategies
9.3 GlaxoSmithKline (GSK)
9.3.1 Business Description
9.3.2 Financial Overview
9.3.3 Business Strategies
9.4 Pfizer Inc.
9.4.1 Business Description
9.4.2 Financial Overview
9.4.3 Business Strategies
10. About Us

8. List of Charts
Figure 1: Pathways of Migraine
Table 1: Other Types of Migraines
Figure 2: Global Migraine Drugs Market Size (US$ Billion), 2009-2013
Figure 3: Forecast of Global Migraine Drugs Market (US$ Billion), 2014-2019
Figure 4: Segmentation of Migraine Drugs by Types, 2013
Table 2: Types of Triptans Currently Available
Table 3: Effectiveness of Oral Triptans
Table 4: Frequency of Oral Triptan Side Effects
Table 5: Triptan Costs
Table 6: Tezampanel Drug Market, 2013
Figure 5: Prevalence of Migraine Worldwide (2007-2013)
Figure 6: Total Number of Migraine Sufferers in the US in Million, 2012E-2017E
Figure 7: The US Migraine Drugs Market Size (US$ Billion), 2009
Figure 8: Share of the US in Overall Migraine Drugs Market, 2013
Figure 9: Market Shares of Triptan by Brands, 2013
Table 7: Estimated Sales of Selected Migraine Drugs in the US, 2013
Figure 10: Global Healthcare Expenditures Per Capita in US$, 2007-2013
Figure 11: World Population Ages Between 15-34 Years in Billion, 2007-2013
Table 8: Generic Availability of Select Migraine Products
Figure 12: Global BOTOX Migraine Sales in US$ Million, 2012-2017

9. Figure 13: BOTOX Migraine Sales by Geography in US$ Million, 2012-2017
Table 9: New Products for the Treatment and Prevention of Migraine
Figure 14: Migraine Drugs Share in Total Prescriptions, Nov 2012 vs Nov 2013
Figure 15: Migraine Drugs Share in Total Prescriptions (Excl acetaminophen products) by Players, Nov 2012 vs
Nov 2013
Figure 16: Endo International Plc.- Revenue Segmentation by Business Segments, 2013
Table 10: Revenue Breakdown of Endo Pharmaceuticals Segment, 2013
Figure 17: Endo International Plc - Revenues from “Frova” (US$ Million) 2010-2013
Figure 18: Impax Laboratories – Revenue Segmentation by Business Segments, 2013
Figure 19: Revenue from Impax Division Segment, 2010-2013 (US$ Million)
Figure 20: GSK Revenue Segmentation by Business Areas, 2013
Figure 21: GSK- Revenues from Imigran/Imitrex Migraine Drugs Brands (US$ Million) 2011-2013
Figure 22: GSK- Distribution of Imigran/Imitrex Migraine Drugs by Geographic Areas, 2013
Figure 23: Pfizer’s Revenue Share by Business Segments (2013)
Figure 24: Pfizer – Revenues from Relpax Migraine Drug (US$ Million), 2011-2013
List of Charts

10. Daedal Research
Daedal Research is a research and consulting firm specialized in providing research reports and
customized business research and analysis. The research firm offers a blend of the best strategic
consulting and market research solutions, which promise data rich, cost effective, and highly
insightful analysis to help its clients with perfect answers to their important business queries.
For more details please contact Mr. Rajeev Kumar:
Tel: +91-120-4553017 (9.30 am - 6.30 pm) IST
Mobile: +91-8743975789 (24 X7)
Enquiries: info@daedal-research.com
Title: Global Anti-Migraine DrugsMarket: Trends & Opportunities (2014-19)
Published: June 2014
Pages: 60
Price: US$ 800 (Single-User License)
: US$ 1600 (Corporate License)
For placing an order of the Report, please press the following link:
http://www.daedal-research.com/global-anti-migraine-drugs-market-trends-and-opportunities-2014-192